Leonteq Securities AG’s Alexion Pharmaceuticals ALXN Stock Holding History

Leonteq Securities AG’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-830	Closed	-$152K	–	1257
2021 Q2	$152K	Sell	830 -378	-31%	-$64.9K	0.01%	628
2021 Q1	$185K	Sell	1,208 -85	-7%	-$13.1K	0.01%	566
2020 Q4	$202K	Buy	+1,293	New	+$166K	0.01%	567

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Leonteq Securities AG's ALXN Position: Q3 2021 in Review

Leonteq Securities AG sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 830 shares — an estimated $152K sold.

Leonteq Securities AG first reported a position in ALXN in Q4 2020 and held it in 3 quarters. The position peaked at $202K in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Leonteq Securities AG reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Leonteq Securities AG sold 830 Alexion Pharmaceuticals shares in Q3 2021, an estimated $152K.
Leonteq Securities AG first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 3 quarters.
Leonteq Securities AG's Alexion Pharmaceuticals position peaked at $202K in Q4 2020.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Leonteq Securities AG's 13F filing for Q3 2021, filed 26 Mar 2026.